Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: RXGOLF who wrote (21456)	5/27/1998 7:50:00 PM
From: Machaon	Read Replies (4) \| Respond to of 32384

Greg, this was pretty good reading: ===> Additional Studies with Panretin Capsules << "Phase II trials with Panretin capsules are ongoing in breast and pediatric cancers, and in bronchial metaplasia. A trial in myelodysplastic syndrome and in severe plaque psoriasis have been completed. The results of the ongoing studies are expected to be announced in 1998 and may support additional studies upon which additional NDAs could be based. In addition, Panretin capsules are planned to be studied in a European trial in patients with acute promyelocytic leukemia." >> There certainly is a lot going on! What do you think tomorrows action is going to be like? Will LGND jump up, on the news, and then settle back to around $14 (like always)? Or will this mark the start of LGND's fourth straight Spring/Summer rally? Being a Yea-sayer, who would like to make some more money on LGND, you know which one I'd prefer. <G> Good luck, Bob